Compare ResMed Inc. (RMD) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.2. The key difference: ResMed Inc. pays a 1.19% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none, and ResMed Inc. is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| RMD | YMAG | |
|---|---|---|
Market Cap | $31.89B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $283.28 | $15.98 |
52-Week Low | $182.82 | $10.76 |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
YMAG trades at $11.26, down slightly (-0.18%) on the day. The technical outlook is bullish with moving averages supporting upward momentum, though oscillators remain neutral. The ETF maintains a consistent weekly dividend distribution strategy, with recent payouts ranging from $0.07 to $0.11 per share. Recent news highlights YieldMax's ongoing distribution announcements and trading activity, with the stock showing 2.7% gains in recent sessions according to Defense World (August 4, 2026).
The outlook remains positive given the bullish technical signals and consistent income generation through dividends. However, investors should monitor NAV stability during earnings periods as noted by Seeking Alpha (July 28, 2026). Key risks include option strategy execution and market volatility affecting the underlying Magnificent 7 components. The ETF's performance remains tied to successful option income generation and component stock stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
